RT Journal Article
SR Electronic
T1 Cooccurrence of N501Y, P681R and other key mutations in SARS-CoV-2 Spike
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.25.21268404
DO 10.1101/2021.12.25.21268404
A1 C. Lee
A1 S. Mangalaganesh
A1 L.O.W. Wilson
A1 M.J. Kuiper
A1 T.W. Drew
A1 S.S. Vasan
YR 2021
UL http://medrxiv.org/content/early/2021/12/27/2021.12.25.21268404.abstract
AB The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has produced five variants of concern (VOC) to date. The important Spike mutation ‘N501Y’ is common to Alpha, Beta, Gamma and Omicron VOC, while the ‘P681R’ is key to Delta’s spread. We have analysed circa 4.2 million SARS-CoV-2 genome sequences from the world’s largest repository ‘Global Initiative on Sharing All Influenza Data (GISAID)’ and demonstrated that these two mutations have cooccurred on the Spike ‘D614G’ mutation background at least 3,678 times from 17 October 2020 to 1 November 2021. In contrast, the Y501-H681 combination, which is common to Alpha and Omicron VOC, is present in circa 1.1 million entries. Two-thirds of the 3,678 cooccurrences were in France, Turkey or US (East Coast), and the rest across 57 other countries. 55.5% and 4.6% of the cooccurrences were Alpha’s Q.4 and Gamma’s P.1.8 sub-lineages acquiring the P681R; 10.7% and 3.8% were Delta’s B.1.617.2 lineage and AY.33 sub-lineage acquiring the N501Y; the remaining 10.2% were in other variants. Despite the selective advantages individually conferred by N501Y and P681R, the Y501-R681 combination counterintuitively did not outcompete other variants in every instance we have examined. While this is a relief to worldwide public health efforts, in vitro and in vivo studies are urgently required in the absence of a strong in silico explanation for this phenomenon. This study demonstrates a pipeline to analyse combinations of key mutations from public domain information in a systematic manner and provide early warnings of spread.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by funding (Principal Investigator: S.S.V.) from the CSIRO Future Science Platforms, National Health and Medical Research Council (MRF2009092), and United States Food and Drug Administration (FDA) Medical Countermeasures Initiative contract (75F40121C00144); and by funding (Principal Investigator: L.O.W.W.) from the Australian Academy of Science and the Australian Department of Industry, Science, Energy and Resources. The article reflects the views of the authors and does not represent the views or policies of the funding agencies including the FDA.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study does not involve any human samples, identifiable human data or patient records. It only involves bioinformatics analysis of novel coronavirus genome sequences openly accessible from the public repository GISAID, and these sequences do not contain any metadata that can be identified with any individual. This includes sample collection dates and anonymous sample IDs that are openly accessible. Our study does not report any exact age or photographs. Clinical trial registration is not applicable as this is neither an interventional study nor an observational study involving humans.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis paper only uses publicly accessible data that can be downloaded from GISAID, the largest repository of SARS-CoV-2 genome sequences. The lists of GISAID EPI_ISL_ sample IDs and data used by our analysis can be requested from the corresponding author. Our Python code is available at https://github.com/Carol-Lee-gh/Covid-Mutation-Pipieline.git. https://github.com/Carol-Lee-gh/Covid-Mutation-Pipieline.git